Acotec Scientific Holdings (HKG:6669) Full Year 2024 Results
Key Financial Results
- Revenue: CN¥534.0m (up 13% from FY 2023).
- Net income: CN¥52.3m (up 261% from FY 2023).
- Profit margin: 9.8% (up from 3.1% in FY 2023). The increase in margin was driven by higher revenue.
- EPS: CN¥0.17 (up from CN¥0.048 in FY 2023).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Acotec Scientific Holdings Revenues and Earnings Miss Expectations
Revenue missed analyst estimates by 6.5%. Earnings per share (EPS) also missed analyst estimates by 35%.
The company's shares are down 9.6% from a week ago.
Balance Sheet Analysis
Just as investors must consider earnings, it is also important to take into account the strength of a company's balance sheet. We've done some analysis and you can see our take on Acotec Scientific Holdings' balance sheet.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.